POLL: Which Recent FDA Update Was Most Exciting?

Poll

Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
Dupilumab FDA Approved for AD Patients 6 months to 5 years
TMB-001 Granted FDA Breakthrough Therapy Designation
FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
Tapinarof Cream 1% is FDA Approved
Related Videos
infectious disease
Related Content

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Arcutis Submits sNDA for Roflumilast Cream in the Treatment of Atopic Dermatitis in Patients 6 and Older

September 12th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination With Pembrolizumab for Resected Stage IIB-IV Melanoma

July 27th 2023

Ritlecitinib and Nivolumab Receive Positive CHMP Opinions

July 24th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Arcutis Submits sNDA for Roflumilast Cream in the Treatment of Atopic Dermatitis in Patients 6 and Older

September 12th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination With Pembrolizumab for Resected Stage IIB-IV Melanoma

July 27th 2023

Ritlecitinib and Nivolumab Receive Positive CHMP Opinions

July 24th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Arcutis Submits sNDA for Roflumilast Cream in the Treatment of Atopic Dermatitis in Patients 6 and Older

September 12th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

Merck and Moderna Initiate Phase 3 Study Evaluating V940 in Combination With Pembrolizumab for Resected Stage IIB-IV Melanoma

July 27th 2023

Ritlecitinib and Nivolumab Receive Positive CHMP Opinions

July 24th 2023
© 2023 MJH Life Sciences

All rights reserved.